Genome Mining of Salinispora Uncovers a Repertoire of Secondary Metabolites and Carbohydrate-Active Enzymes

Natural products derived from microorganisms are a significant part of the pharmaceutical industrys arsenal today. These efforts have increasingly centred on marine microbes, which have produced a variety of intriguing novel chemicals. Marine-derived strains are likely candidates for natural product discovery since actinomycetes are a significant source of microbially produced natural compounds. The availability of microbial genome sequencing has revealed a number of natural products (NPs) that have not yet been thoroughly investigated. The genome mining potential of the genus Salinispora, which has potential for the production of secondary metabolites of clinical importance, remains unexplored. In this study, we have demonstrated a thorough comprehension of the genetic characteristics, biosynthetic gene clusters (BGCs), and genetic clusters for carbohydrate-active enzymes found in the Salinispora genomes. In our analysis, we have identified 686 BGCs, among which 3.79% are identical to the BGCs that produce ketomemicin B3/ketomemicin B4, salinilactam, lymphostin/neolymphostinol B/lymphostinol/neolymphostin B, benzastatin, and thiolactomycin. We have found 19.5% of the BGCs, which are only present in the genomes of Salinispora and may open the door to the development of novel drugs. We have also found a total of 3604 genes in 62 various categories of the six major carbohydrate-active enzymes. The development of new-generation bioactive compounds that are significant for biotechnology relies heavily on the scientific insights provided by genome mining in this genus.